Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment
- 23 January 2021
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 28 (5) , 787-794
Abstract
Carcinogenesis risk scores for chronic hepatitis B have been proposed, but it remains unclear whether these scores during nucleoside/nucleotide analogue (NA) therapy are useful for risk assessment. In this study, we examined changes of these scores and the predictability during NA treatment. 432 patients with no history of hepatocellular carcinoma (HCC) treated with NA were enrolled. PAGE‐B, modified PAGE‐B (mPAGE‐B), and REACH‐B scores were calculated at NA administration, 1 and 2 years after administration. The median follow‐up duration was 5.1 years, during which 37 patients (8.6%) developed HCC. Cumulative incidence HCC development in patients with high risk of PAGE at NA administration, and 1 and 2 years after NA administration was significantly higher than those with intermediate and low‐risk groups (p < .05 for all time points), whereas HCC incidence in patients with high risk of mPAGE‐B and REACH‐B at 2 years after NA administration were equivalent to those with intermediate and low‐risk groups (p = .2 for mPAGE‐B, and p = .1 for REACH‐B). The area under the receiver operating characteristic (AUROC) for HCC development of PAGE‐B at NA administration, and 1 and 2 years after administration were 0.773, 0.803 and 0.737, respectively. The AUROCs of PAGE‐B at each point were continuously higher than those of REACH‐B (0.646, 0.725, and 0.653, respectively) and mPAGE‐B (0.754, 0.734, and 0.678, respectively).PAGE‐B score has a high diagnostic accuracy for HCC development at any time point during NA treatment, indicating its potential use as a real‐time monitor of HCC development.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP19fk0210025h0003, JP20fk0210067h0001)
- Uehara Memorial Foundation
This publication has 37 references indexed in Scilit:
- Artificial liver treatment improves survival in patients with hepatitis B virus‐related acute‐on‐chronic liver failure: A case‐control matched analysisHepatology Research, 2020
- Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis BJournal of Medical Virology, 2020
- Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovirJGH Open, 2019
- Entecavir treatment of hepatitis B virus‐infected patients with severe renal impairment and those on hemodialysisHepatology Research, 2019
- Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis BJournal of Medical Virology, 2019
- Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarateJournal of Gastroenterology and Hepatology, 2019
- Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapyJournal of Hepatology, 2018
- Suppression of hepatitis B surface antigen production by combination therapy with nucleotide analogues and interferon in children with genotype C hepatitis B virus infectionHepatology Research, 2018
- PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapyJournal of Hepatology, 2016
- Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: A propensity score analysisJournal of Hepatology, 2013